Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WEE1 | P30291 | 12/20 | 0.50 |
| ▸ | BTK | Q06187 | 5/20 | 0.41 |
| ▸ | PKMYT1 | Q99640 | 3/20 | 0.39 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.37 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29310246 | 1.00 | WEE1 (0.50) | WEE1BTKPKMYT1SLC2A1SYK | |
| SCHEMBL29310234 | 0.88 | SLC2A1 (0.42) | WEE1BTKPKMYT1SLC2A1SYK | |
| SCHEMBL29310239 | 0.86 | SLC2A1 (0.42) | WEE1BTKPKMYT1SLC2A1SYK | |
| SCHEMBL30997619 | 0.81 | WEE1 (0.43) | WEE1BTKPKMYT1SLC2A1SYK | |
| SCHEMBL29310241 | 0.81 | WEE1 (0.43) | WEE1BTKPKMYT1SLC2A1SYK | |
| SCHEMBL29310236 | 0.81 | BTK (0.49) | WEE1BTKPKMYT1SLC2A1SYK | |
| SCHEMBL29310230 | 0.81 | WEE1 (0.48) | WEE1BTKSLC2A1SYK | |
| SCHEMBL30997635 | 0.81 | WEE1 (0.49) | WEE1PKMYT1SLC2A1SYK | |
| SCHEMBL29310208 | 0.81 | WEE1 (0.49) | WEE1PKMYT1SLC2A1SYK | |
| SCHEMBL24773978 | 0.79 | BTK (0.42) | BTKSLC2A1SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228459-A1 | WEE1 INHIBITORS AND USES THEREOF | BOUNDLESS BIO, INC. | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228459-A1 | WEE1 INHIBITORS AND USES THEREOF | WEE1, WEE2, DCLRE1B | WEE1 1/4885BTK 2297/4885PKMYT1 1740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.